Yizun Biotech

Yizun Biotech is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative CAR-T cell therapies for solid tumors and hematological malignancies. The company utilizes a proprietary non-viral gene integration platform to enhance the safety and efficacy of its cell products while significantly reducing manufacturing costs compared to viral-based methods. Its lead candidate, YZ-101, targets mesothelin and is currently being evaluated in clinical trials for difficult-to-treat indications such as pancreatic and ovarian cancer. Yizun Biotech aims to overcome the traditional barriers of CAR-T therapy in solid tumors through advanced engineering, multi-target strategies, and universal CAR-T (UCAR-T) technologies. The company is supported by prominent venture capital firms and maintains a robust pipeline of next-generation immune cell therapies.